Insight

Aditya Juloori: Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer

Photo taken from Aditya Juloori/X

Aug 14, 2024, 13:00

Aditya Juloori: Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer

Aditya Juloori, Radiation Oncologist at The University of Chicago Medical Center, shared on X:

“Check out our multi-center phase 2 IIT currently accruing for upfront SBRT added to Durvalumab-based chemoimmunotherapy for the first line treatment of extensive stage SCLC – the DARES trial.”

DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer

Authors: Christine M. Bestvina, Jared H. L. Hara, Theodore Karrison, Benjamen Bowar, Janet Chin, Marina C. Garassino, Sean P. Pitroda, Rajat Thawani, Everett E. Vokes, Gregory Gan, Jun Zhang, Andrew M. Baschnagel, Toby C. Campbell, Steven Chmura and Aditya Juloori.

Source: Aditya Juloori/X

Aditya Juloori cancer DARES trial Durvalumab Durvalumab-based chemoimmunotherapy multi-center trial OncoDaily Oncology SCLC The University of Chicago Medical Center

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage